东菱精纯克栓酶治疗急性脑梗塞的对照试验

Comparative Study on the Effectiveness of Tobishi Pure Thrombolysase on Acute Cerebral Infarction

应用日本东菱精纯克栓酶治疗急性脑梗塞20例,与“传统”或“常规”治疗30例进行对照性研究。结果显示,克栓酶治疗组在用药后第3、7、14及28天卒中患者神经功能缺损程度评分均明显低于对照组,经统计学处理具有显著性差异,表明克栓酶治疗见效快、疗效好。提出溶栓治疗后继续应用其他脑血管病药物的联合治疗方法,并就东菱精纯克栓酶的作用机制进行了探讨。

20 cases of acute cerebral infarct were treated by Tobishi pure thrombolysase (Japan) and the results were compared with those of 'traditional' or 'regular' treatment- The results showed that the scores in the defect of nerve function 3, 7, 14 and 28 days after treatment were significantly lower than those of control group. The tobishi pure thrombolysase treatment showed a quick action and good effect. The combination use of other drugs for cerebral disorder after thrombolytic treatment is advocated. The mechanism of tobishi pure thrombolysase action was also discussed.